Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in
combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced
cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will
be administered after or during chemoradiation.